BioAge Labs, Inc.

BIOA
$15.42 (- $0.38 - 2.41%)
Last updated: 2026-06-10 18:46 UTC
BIOA Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS09077V1008
CUSIP09077V100
Market Price15.42
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio0.97
EPS13.61
Market Cap$473.6M
Book Value7.74
Price to Book1.707
BetaN/A
52w High13.68
52w Low2.88
Next Earnings DateN/A

BioAge Labs, Inc. trades under ticker BIOA on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US09077V1008, CUSIP 09077V100.

About the Company
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Price History